157 related articles for article (PubMed ID: 15989496)
21. Alosetron and irritable bowel syndrome.
Mayer EA; Bradesi S
Expert Opin Pharmacother; 2003 Nov; 4(11):2089-98. PubMed ID: 14596662
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review.
Binienda A; Storr M; Fichna J; Salaga M
Curr Drug Targets; 2018; 19(15):1774-1781. PubMed ID: 29284389
[TBL] [Abstract][Full Text] [Related]
23. Irritable bowel syndrome: update on pathogenesis and management.
Alaradi O; Barkin JS
Med Princ Pract; 2002; 11(1):2-17. PubMed ID: 12116690
[TBL] [Abstract][Full Text] [Related]
24. Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective.
Tack J; Fried M; Houghton LA; Spicak J; Fisher G
Aliment Pharmacol Ther; 2006 Jul; 24(2):183-205. PubMed ID: 16842448
[TBL] [Abstract][Full Text] [Related]
25. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
[TBL] [Abstract][Full Text] [Related]
26. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.
Hasler WL; Schoenfeld P
Drug Saf; 2004; 27(9):619-31. PubMed ID: 15230644
[TBL] [Abstract][Full Text] [Related]
27. Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome.
Lucak SL
Therap Adv Gastroenterol; 2010 May; 3(3):165-72. PubMed ID: 21180598
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
[TBL] [Abstract][Full Text] [Related]
29. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
Moskwa A; Boznańska P
Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
[TBL] [Abstract][Full Text] [Related]
30. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
Gale JD
Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in pharmacological research on the management of irritable bowel syndrome.
Nam Y; Min YS; Sohn UD
Arch Pharm Res; 2018 Oct; 41(10):955-966. PubMed ID: 30132170
[TBL] [Abstract][Full Text] [Related]
32. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds.
Callahan MJ
J Clin Gastroenterol; 2002 Jul; 35(1 Suppl):S58-67. PubMed ID: 12184141
[TBL] [Abstract][Full Text] [Related]
33. Cilansetron: KC 9946.
Drugs R D; 2005; 6(3):169-73. PubMed ID: 15869320
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
[TBL] [Abstract][Full Text] [Related]
35. Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome.
Harris LA; Chang L
Womens Health (Lond); 2007 Jan; 3(1):15-27. PubMed ID: 19803861
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.
Zheng Y; Yu T; Tang Y; Xiong W; Shen X; Jiang L; Lin L
PLoS One; 2017; 12(3):e0172846. PubMed ID: 28291778
[TBL] [Abstract][Full Text] [Related]
37. [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].
Komoto S; Miura S
Nihon Rinsho; 2006 Aug; 64(8):1487-90. PubMed ID: 16898618
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.
Ford AC; Brandt LJ; Young C; Chey WD; Foxx-Orenstein AE; Moayyedi P
Am J Gastroenterol; 2009 Jul; 104(7):1831-43; quiz 1844. PubMed ID: 19471254
[TBL] [Abstract][Full Text] [Related]
39. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Cash BD; Lacy BE; Rao T; Earnest DL
Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
[TBL] [Abstract][Full Text] [Related]
40. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
